5000万円、一度で済む白血病の治療薬・・がFDAにより承認されました。（たけっ！）
商品名：Kymriah
一般名：tisagenlecleucel
白血病細胞が持つCD19抗原を攻撃するタンパク、CAR proteinを作らせる遺伝子を免疫細胞に入れるらしい・・です。
The FDA on Wednesday approved a chimeric antigen receptor (CAR) T-cell therapy for treatment of certain pediatric and young adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
Calling it a "historic action," the agency said the approval marks the "first gene therapy available in the United States."
The treatment, to be tradenamed Kymriah and carrying the generic name tisagenlecleucel, is sold by Novartis. The company said it will charge $475,000 for the one-time treatment.
In this type of therapy, patients' own immune cells are modified ex vivo to include a gene for the CAR protein, which directs them to attack leukemia cells carrying the CD19 antigen.
これもあ感染症屋にBusinessをくれるのかな・・
詳細は以下をどぞ。
https://www.medpagetoday.com/HematologyOncology/Leukemia/67615?xid=NL_breakingnews_2017-08-30&eun=g975415d0r
ちなみに全国的に今日で8月が終わります。すなわち2017年の2/3が終了します。
商品名：Kymriah
一般名：tisagenlecleucel
白血病細胞が持つCD19抗原を攻撃するタンパク、CAR proteinを作らせる遺伝子を免疫細胞に入れるらしい・・です。
The FDA on Wednesday approved a chimeric antigen receptor (CAR) T-cell therapy for treatment of certain pediatric and young adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
Calling it a "historic action," the agency said the approval marks the "first gene therapy available in the United States."
The treatment, to be tradenamed Kymriah and carrying the generic name tisagenlecleucel, is sold by Novartis. The company said it will charge $475,000 for the one-time treatment.
In this type of therapy, patients' own immune cells are modified ex vivo to include a gene for the CAR protein, which directs them to attack leukemia cells carrying the CD19 antigen.
これもあ感染症屋にBusinessをくれるのかな・・
詳細は以下をどぞ。
https://www.medpagetoday.com/HematologyOncology/Leukemia/67615?xid=NL_breakingnews_2017-08-30&eun=g975415d0r
ちなみに全国的に今日で8月が終わります。すなわち2017年の2/3が終了します。
